肥厚型心肌病合并左室收缩功能障碍:SHaRe注册研究解读
基于国际SHaRe注册研究6793例肥厚型心肌病患者,553例(8%)符合左室收缩功能障碍(LVSD,LVEF<50%)标准。75%患者发生临床相关事件,35%达到复合终点(全因死亡、心脏移植或左室辅助装置植入),中位时间8.4年。多致病性肌节变异、房颤和LVEF<35%是复合终点显著预测因素。
要点
- HCM-LVSD约占HCM患者的8%,75%发生临床相关事件,35%达复合终点。
- 多致病性肌节变异(HR 5.6)、房颤(HR 2.6)、LVEF<35%(HR 2.0)预测复合终点。
- 15年新发HCM-LVSD累积发生率约7.5%,薄丝蛋白基因变异预测新发风险。
核心结论
- HCM-LVSD影响约8%的HCM患者,自然病程个体差异大,但75%经历不良事件,35%发生死亡等复合终点,中位时间8.4年。
研究设计与样本
- 国际SHaRe注册研究(11个高容量HCM中心)纳入6793例HCM患者,其中553例(8%)符合HCM-LVSD标准(LVEF<50%)。
- 采用Cox比例风险模型识别预后及新发HCM-LVSD的预测因素。
主要发现
- HCM-LVSD患者中75%发生临床相关事件,35%达到复合终点(全因死亡n=128、心脏移植n=55、左室辅助装置植入n=9)。
- 识别HCM-LVSD后至复合终点中位时间8.4年,但自然病程个体差异显著。
- 复合终点显著预测因素:多致病/可能致病肌节变异(HR 5.6,95%CI 2.3-13.5)、房颤(HR 2.6,95%CI 1.7-3.5)、LVEF<35%(HR 2.0,95%CI 1.3-2.8)。
- 15年内新发HCM-LVSD发生率约7.5%。
- 新发HCM-LVSD显著预测因素:较大左室腔径(HR 1.1,95%CI 1.0-1.3)、室壁厚度(HR 1.3,95%CI 1.1-1.4)、基线LVEF 50%-60%(HR 1.8-2.8)、心脏磁共振晚期钆增强(HR 2.3,95%CI 1.0-4.9)、致病/可能致病肌节变异(薄丝蛋白基因HR 2.5,95%CI 1.2-5.1)。
关键数值与推荐
- HCM-LVSD定义为左心室射血分数<50%。
- 复合终点包括全因死亡、心脏移植或左室辅助装置植入。
临床怎么用
- 对HCM患者应评估LVEF以识别HCM-LVSD,LVEF<50%即符合定义。
- 携带多致病肌节变异、房颤或LVEF<35%的HCM-LVSD患者预后更差,需密切监测。
- 基线LVEF 50%-60%、较大左室腔径、室壁厚度、晚期钆增强及薄丝蛋白基因变异提示新发HCM-LVSD风险较高。
局限性
- HCM-LVSD相对罕见,自然病程尚未完全明确。
- 研究来自高容量HCM专科中心,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The term "end stage" has been used to describe hypertrophic cardiomyopathy (HCM) with left ventricular systolic dysfunction (LVSD), defined as occurring when left ventricular ejection fraction is <50%. The prognosis of HCM-LVSD has reportedly been poor, but because of its relative rarity, the natural history remains incompletely characterized. METHODS: Data from 11 high-volume HCM specialty centers making up the international SHaRe Registry (Sarcomeric Human Cardiomyopathy Registry) were used to describe the natural history of patients with HCM-LVSD. Cox proportional hazards models were used to identify predictors of prognosis and incident development. RESULTS: From a cohort of 6793 patients with HCM, 553 (8%) met the criteria for HCM-LVSD. Overall, 75% of patients with HCM-LVSD experienced clinically relevant events, and 35% met the composite outcome (all-cause death [n=128], cardiac transplantation [n=55], or left ventricular assist device implantation [n=9]). After recognition of HCM-LVSD, the median time to composite outcome was 8.4 years. However, there was substantial individual variation in natural history. Significant predictors of the composite outcome included the presence of multiple pathogenic/likely pathogenic sarcomeric variants (hazard ratio [HR], 5.6 [95% CI, 2.3-13.5]), atrial fibrillation (HR, 2.6 [95% CI, 1.7-3.5]), and left ventricular ejection fraction <35% (HR, 2.0 [95% CI, 1.3-2.8]). The incidence of new HCM-LVSD was ≈7.5% over 15 years. Significant predictors of developing incident HCM-LVSD included greater left ventricular cavity size (HR, 1.1 [95% CI, 1.0-1.3] and wall thickness (HR, 1.3 [95% CI, 1.1-1.4]), left ventricular ejection fraction of 50% to 60% (HR, 1.8 [95% CI, 1.2, 2.8]-2.8 [95% CI, 1.8-4.2]) at baseline evaluation, the presence of late gadolinium enhancement on cardiac magnetic resonance imaging (HR, 2.3 [95% CI, 1.0-4.9]), and the presence of a pathogenic/likely pathogenic sarcomeric variant, particularly in thin filament genes (HR, 1.5 [95% CI, 1.0-2.1] and 2.5 [95% CI, 1.2-5.1], respectively). CONCLUSIONS: HCM-LVSD affects ≈8% of patients with HCM. Although the natural history of HCM-LVSD was variable, 75% of patients experienced adverse events, including 35% experiencing a death equivalent an estimated median time of 8.4 years after developing systolic dysfunction. In addition to clinical features, genetic substrate appears to play a role in both prognosis (multiple sarcomeric variants) and the risk for incident development of HCM-LVSD (thin filament variants).
引用
- Marstrand P, Han L, Day SM, et al. Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Insights From the SHaRe Registry. Circulation. 2020. PMID: 32228044. doi:10.1161/CIRCULATIONAHA.119.044366
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。